Vascular Endothelial Growth Factor Level as a Prognostic Determinant of Small Cell Lung Cancer in Japanese Patients

DOI Web Site Web Site PubMed 参考文献72件 オープンアクセス
  • HASEGAWA Yukihiro
    Second Department of Internal Medicine, Hirosaki University School of Medicine
  • TAKANASHI Shingo
    Second Department of Internal Medicine, Hirosaki University School of Medicine
  • OKUDERA Koichi
    Second Department of Internal Medicine, Hirosaki University School of Medicine
  • KUMAGAI Mika
    Second Department of Internal Medicine, Hirosaki University School of Medicine
  • HAYASHI Akihito
    Second Department of Internal Medicine, Hirosaki University School of Medicine
  • MORIMOTO Takeshi
    Second Department of Internal Medicine, Hirosaki University School of Medicine
  • OKUMURA Ken
    Second Department of Internal Medicine, Hirosaki University School of Medicine

この論文をさがす

説明

Objective To clarify the clinical significance of vascular endothelial growth factor (VEGF) in Japanese patients with small cell lung cancer (SCLC).<Br>Materials and Methods We measured serum VEGF levels using an enzyme-linked immunosorbent assay in 45 patients with SCLC before treatment and in 38 patients with benign pulmonary disease and in 32 healthy subjects (71 non-malignant subjects). VEGF immunostaining was performed in tissue biopsies obtained from 23 SCLC patients during bronchoscopic examination.<Br>Results Median serum VEGF level was 332 pg/ml in patients with SCLC and 160 pg/ml in non-malignant subjects, respectively. The 95% cut-off level to exclude non-malignant subjects was 500 pg/ml. An elevated VEGF level (>500 pg/ml) was found more frequently in patients with extensive disease of SCLC than in those with the limited disease (p<0.01). A significant positive correlation was found between the serum VEGF level and platelet count in SCLC patients (r=0.389; p=0.0083). Serum VEGF level also correlated with serum lactate dehydrogenase in SCLC patients (r=0.381; p=0.0098). However, it did not correlate with serum neuron-specific enolase and pro-gastrin-releasing peptide level. Patients with the elevated VEGF levels had significantly shorter progression-free time than those with the normal VEGF levels (p<0.05). Patients with the elevated VEGF levels had a significantly shorter overall survival time than those with the normal VEGF levels in univariate survival analysis (p<0.05). Further, the elevated VEGF level remained as a significant determinant of poor survival in multivariate analysis (p<0.01). Serum VEGF level was significantly higher in patients with positive VEGF protein immunoreactivity in tumor tissue in SCLC.<Br>Conclusion Elevated serum VEGF levels were associated with poor outcome in SCLC.

収録刊行物

  • Internal Medicine

    Internal Medicine 44 (1), 26-34, 2005

    一般社団法人 日本内科学会

参考文献 (72)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ